kleo
pharmaceuticals
present
bioscience
pipeline
innovation
connecticut
age
covid
conference
new
globe
newswire
kleo
pharmaceuticals
targeted
immunotherapy
company
developing
fully
synthetic
bispecific
therapies
redirect
enhance
replace
antibodies
announced
present
today
local
stakeholders
bioscience
pipeline
innovation
connecticut
age
covid
conference
monday
september
et
event
sponsored
bioct
phrma
bipartisan
bioscience
caucus
doug
manion
md
ceo
chairman
board
kleo
pharmaceuticals
provide
overview
kleo
clinical
programs
focus
monoclonal
antibody
therapy
enhancer
matetm
platform
developed
target
link
live
webcast
company
presentation
available
kleo
lead
program
entering
phase
clinical
studies
multiple
myeloma
multiple
settings
company
second
program
targeting
human
globulin
mimic
hgm
funded
million
grant
bill
melinda
gates
foundation
expected
begin
clinical
testing
early
additional
treatments
development
kleo
pharmaceuticals
kleo
pharmaceuticals
targeted
immunotherapy
company
develops
fully
synthetic
bispecific
therapies
redirect
enhance
replace
antibodies
company
founded
groundbreaking
research
scientific
founder
david
spiegel
yale
university
kleo
synthetic
immunotherapy
platform
uses
two
approaches
molecule
arm
multitargeted
antibody
therapy
enhancer
mate
help
redirect
stimulate
key
components
immune
system
eradicate
cancer
cells
virulent
pathogens
compared
biologic
therapies
kleo
compounds
smaller
versatile
allowing
better
tumor
tissue
penetration
improved
safety
higher
dose
levels
efficient
produce
potentially
orally
bioavailable
optimized
specified
biological
targets
combined
existing
therapies
kleo
investors
include
biohaven
pharmaceutical
holding
company
nyse
bhvn
peptidream
nikkei
pptdf
information
visit
contact
information
lifesci
advisors
investors
irina
koffler
ikoffler
susan
kinkead
media
susan
